Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2026-07-24 17:26:12 ET · period of report 2026-07-22 · accession 0001193125-26-316279 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-24 17:26 | 2026-07-22 | NTLA | Dulac Edward J III | EVP, CFO | S - Sale | $11.25 | -8,111 | 148.2K | -5% | -$91.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-22 | S | D | 8,111 | $11.25 | 148,175 | D | — | — | (F1) Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price. |